Apostolos Stathopoulos
Algemeen Directeur bij Epitopoietic Research Corp.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Bernard Alliaume | M | - |
Epitopoietic Research Corp.
Epitopoietic Research Corp. BiotechnologyHealth Technology Part of ERC-Belgium SA, Epitopoietic Research Corp. is a clinical stage emerging bio-pharmaceutical company based in Pasadena, CA. The company is developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with glioblastoma multiforme (GBM), the most deadliest form of brain cancer, using its patented Gliovac/ERC1671 vaccine. The company was founded by Bernard Alliaume, Apostolos Stathopoulos. Apostolos Stathopoulos has been the CEO since incorporation.
ERC-Belgium SA
ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | 16 jaar |
Bernard Questier | M | - |
Epitopoietic Research Corp.
Epitopoietic Research Corp. BiotechnologyHealth Technology Part of ERC-Belgium SA, Epitopoietic Research Corp. is a clinical stage emerging bio-pharmaceutical company based in Pasadena, CA. The company is developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with glioblastoma multiforme (GBM), the most deadliest form of brain cancer, using its patented Gliovac/ERC1671 vaccine. The company was founded by Bernard Alliaume, Apostolos Stathopoulos. Apostolos Stathopoulos has been the CEO since incorporation.
ERC-Belgium SA
ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | - |
Frédéric Desmedt | M | - |
Epitopoietic Research Corp.
Epitopoietic Research Corp. BiotechnologyHealth Technology Part of ERC-Belgium SA, Epitopoietic Research Corp. is a clinical stage emerging bio-pharmaceutical company based in Pasadena, CA. The company is developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with glioblastoma multiforme (GBM), the most deadliest form of brain cancer, using its patented Gliovac/ERC1671 vaccine. The company was founded by Bernard Alliaume, Apostolos Stathopoulos. Apostolos Stathopoulos has been the CEO since incorporation.
ERC-Belgium SA
ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | - |
Martin Brown | M | - |
Epitopoietic Research Corp.
Epitopoietic Research Corp. BiotechnologyHealth Technology Part of ERC-Belgium SA, Epitopoietic Research Corp. is a clinical stage emerging bio-pharmaceutical company based in Pasadena, CA. The company is developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with glioblastoma multiforme (GBM), the most deadliest form of brain cancer, using its patented Gliovac/ERC1671 vaccine. The company was founded by Bernard Alliaume, Apostolos Stathopoulos. Apostolos Stathopoulos has been the CEO since incorporation.
ERC-Belgium SA
ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | - |
Virgil Schijns | M | - |
ERC-Belgium SA
ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | - |
Joseph Elliot | M | - |
Epitopoietic Research Corp.
Epitopoietic Research Corp. BiotechnologyHealth Technology Part of ERC-Belgium SA, Epitopoietic Research Corp. is a clinical stage emerging bio-pharmaceutical company based in Pasadena, CA. The company is developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with glioblastoma multiforme (GBM), the most deadliest form of brain cancer, using its patented Gliovac/ERC1671 vaccine. The company was founded by Bernard Alliaume, Apostolos Stathopoulos. Apostolos Stathopoulos has been the CEO since incorporation. | - |
Kostia Janssens | M | - |
Epitopoietic Research Corp.
Epitopoietic Research Corp. BiotechnologyHealth Technology Part of ERC-Belgium SA, Epitopoietic Research Corp. is a clinical stage emerging bio-pharmaceutical company based in Pasadena, CA. The company is developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with glioblastoma multiforme (GBM), the most deadliest form of brain cancer, using its patented Gliovac/ERC1671 vaccine. The company was founded by Bernard Alliaume, Apostolos Stathopoulos. Apostolos Stathopoulos has been the CEO since incorporation. | - |
Mohamad Kassas | M | - |
Epitopoietic Research Corp.
Epitopoietic Research Corp. BiotechnologyHealth Technology Part of ERC-Belgium SA, Epitopoietic Research Corp. is a clinical stage emerging bio-pharmaceutical company based in Pasadena, CA. The company is developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with glioblastoma multiforme (GBM), the most deadliest form of brain cancer, using its patented Gliovac/ERC1671 vaccine. The company was founded by Bernard Alliaume, Apostolos Stathopoulos. Apostolos Stathopoulos has been the CEO since incorporation. | - |
Vittorio Lauriente | M | - |
Epitopoietic Research Corp.
Epitopoietic Research Corp. BiotechnologyHealth Technology Part of ERC-Belgium SA, Epitopoietic Research Corp. is a clinical stage emerging bio-pharmaceutical company based in Pasadena, CA. The company is developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with glioblastoma multiforme (GBM), the most deadliest form of brain cancer, using its patented Gliovac/ERC1671 vaccine. The company was founded by Bernard Alliaume, Apostolos Stathopoulos. Apostolos Stathopoulos has been the CEO since incorporation. | - |
D'Halleweyn Wim | M | - |
ERC-Belgium SA
ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | - |
Jean-Bernard D'Harcour | M | - |
ERC-Belgium SA
ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | 16 jaar |
Janssen de la Boëssière-Thiennes Constantine | M | - |
ERC-Belgium SA
ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | - |
Mohammad Kassas | M | - |
ERC-Belgium SA
ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | - |
Vittorio Laurent | M | - |
ERC-Belgium SA
ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | - |
Salvatore Morone | M | - |
ERC-Belgium SA
ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | - |
Little John Paul | M | - |
ERC-Belgium SA
ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
België | 12 | 75.00% |
Verenigde Staten | 8 | 50.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Apostolos Stathopoulos
- Persoonlijk netwerk